As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
This application note presents an independent cost-of-goods (COG) analysis conducted by Decisional Point Limited to evaluate the financial impact of switching from plasmid DNA (pDNA) to Touchlight’s enzymatically produced dbDNA™…
Read More
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
Read More
Unlock how dbDNA™ can reduce AAV gene therapy manufacturing costs and enhance efficiency.
Read More
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Read More
Touchlight’s dbDNA™ enables fast, scalable GMP-grade AAV production with fewer impurities and no bacterial sequences, confirmed by nanopore sequencing.
Read More
dbDNA™: The Future of AAV Production Recombinant adeno-associated virus (AAV) is one of the most promising delivery vehicles for genetic medicines, offering potential to treat a range of previously…
Read More
Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, speed to manufacture, safety and scalability. Many biotech and pharma…
Read More
Discover how synthetic, backbone-free DNA offers a safer, scalable alternative to traditional plasmid DNA for AAV production, addressing key challenges in transfection efficiency, cost, and impurity control. Download the poster…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
